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PLINICAL RESEARCH Interventional Cardiology
irect Stenting of Native De Novo Coronary
rtery Lesions With the Sirolimus-Eluting Stent
Post Hoc Subanalysis of the Pooled E- and C-SIRIUS Trials
ichael Schlüter, PHD,* Joachim Schofer, MD,* Anthony H. Gershlick, MD,† Erick Schampaert, MD,‡
illiam Wijns, MD,§ Günter Breithardt, MD, FACC, for the E- and C-SIRIUS Investigators
amburg and Münster, Germany; Leicester, United Kingdom; Montréal, Canada; and Aalst, Belgium
OBJECTIVES We sought to assess the impact of direct stenting (DS) using the sirolimus-eluting stent
(SES) on angiographic and clinical outcomes.
BACKGROUND The SES is superior to bare-metal stents in the treatment of native de novo coronary artery
lesions in randomized, controlled trials.
METHODS A post hoc analysis was performed on 225 patients (158 men; 62 11 years old) who received
SES in the pooled cohorts of the European and Canadian Sirolimus-Eluting Stent in
Coronary Lesions (E-SIRIUS and C-SIRIUS, respectively) trials. Of these patients, 57
(25%) had undergone DS at the investigator’s discretion. Lesion predilation preceded SES
implantation in the remaining 168 patients.
RESULTS Patient and lesion characteristics were no different between the two subgroups, except for a
lower prevalence of moderate to severe lesion calcification (5% vs. predilation 19%, p 0.017)
and a lower baseline diameter stenosis (61.6% vs. predilation 68.1%, p  0.001) in the DS
subgroup. At eight months, in-lesion late loss (0.10 vs. 0.19 mm at predilation, p 0.14) and
in-lesion binary restenosis (2.0% vs. 6.1% at predilation, p  0.46) tended to be lower after
DS. Clinical follow-up at one year revealed non-significantly reduced incidences of target
lesion revascularization (1.8% vs. 5.4% at predilation, p  0.46) and major adverse cardiac
events (5.3% vs. 8.9% at predilation, p  0.57).
CONCLUSIONS Direct SES deployment performed at the investigator’s discretion was as safe and efficacious
at mid-term follow-up as stenting preceded by lesion predilation. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.04645:10–3) © 2005 by the American College of Cardiology Foundation
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wmprovements in stent design now allow for reliable, safe,
nd cost-effective direct stenting (DS) (1– 4). Outcomes
ith sirolimus-eluting stents (SES) are superior to bare-
etal stents (5– 8). Only the European Sirolimus-Eluting
tent in Coronary Lesions (E-SIRIUS) trial (7) and its
sister” Canadian trial, C-SIRIUS (8), allowed direct
mplantation of the SES. Concern has been expressed
bout the potential drug and/or polymer loss from the
ES when directly implanted, which may reduce efficacy.
his report assesses the feasibility and safety of DS in the
ooled subgroup of patients from the E- and C-SIRIUS
rials.
ETHODS
he E- and C-SIRIUS are parallel trials designed to assess
ong-term clinical outcomes to five years, conducted at 35
enters in Europe and Israel and 8 centers in Canada.
From the *Center for Cardiology and Vascular Intervention, Hamburg, Germany;
Glenfield Hospital, Leicester, United Kingdom; ‡Hôpital du Sacré-Coeur de
ontréal, Montréal, Canada; §Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium; and
he Department of Cardiology and Angiology, Hospital of the University of
ünster, Münster, Germany. This study was sponsored by Cordis, a Johnson &
ohnson Company.s
Manuscript received June 21, 2004; revised manuscript received September 1, 2004,
ccepted September 13, 2004.atient and angiographic inclusion and exclusion criteria
ere identical for both trials (7,8).
atient selection. Of 452 patients enrolled, 225 (158 men;
ean [SD] age 62  11 years) received one or more SES
nd formed the basis of the present prespecified post hoc
nalysis. Direct stenting was performed at 30 of 43 centers
n a total of 57 patients, representing a median of 40%
range 10% to 60%) of patients receiving SES in these
enters and 25.3% of the total SES patient population.
atient and lesion characteristics in the two subgroups are
iven in Table 1.
efinitions. Late loss  the minimum lumen diameter
MLD) after the intervention minus MLD at eight months;
inary restenosis  50% diameter stenosis at follow-up;
ajor adverse cardiac event (MACE)  cumulative inci-
ence of death, myocardial infarction (MI), emergency
oronary artery bypass graft surgery, and ischemia-driven
arget lesion revascularization (TLR).
tatistics. Continuous variables are presented as the mean
alue  SD, except where noted, with subgroup differences
ssessed by the Student t test. Categorical variables are
resented as counts and/or percentages, with differences
etween subgroups assessed by the Fisher exact test (2  2
able) or chi-square test (3  2 table). Event-free survival
as estimated by the Kaplan-Meier method. Statisticalignificance was assumed for a two-sided p value of 5%.
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aseline patient and lesion characteristics. Baseline pa-
ient and lesion characteristics in the DS and predilation
ubgroups were well matched (Table 1). However, the
revalence of moderate-to-severe lesion calcification was
igher in predilated lesions (19% vs. 5%, p  0.017).
ngulation 45° in the proximal vessel was more prevalent
n DS lesions (18% vs. 7%, p  0.036).
rocedural characteristics. Procedure duration and total
uoroscopy time were significantly reduced by DS
Table 2). Stent placement using the chosen approach
as successful in all patients, with no crossovers from
S. Mean total stent lengths were 23.6 and 24.1 mm,
nd multiple stents were implanted in 40% and 51% of
Abbreviations and Acronyms
CI  confidence interval
C-SIRIUS  Canadian Sirolimus-Eluting Stent in
Coronary Lesions trial
DS  direct stenting
E-SIRIUS  European Sirolimus-Eluting Stent in
Coronary Lesions trial
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimum lumen diameter
SES  sirolimus-eluting stent(s)
SIRIUS  Sirolimus-Eluting Stent in Coronary
Lesions trial
TLR  target lesion revascularization
able 1. Baseline Characteristics
Predilation
(n  168)
Direct
Stenting
(n  57)
p
Value
atients
Age (yrs) 62.1  11.3 60.2 11.1 NS
Men 69 74 NS
Diabetes mellitus 21 18 NS
Hypertension 63 57 NS
Hyperlipidemia 79 79 NS
Current smoking 36 39 NS
Previous MI 44 37 NS
Angina pectoris
Exertional angina 45 56 NS
Angina at rest 20 14 NS
Unstable angina 41 26 NS
Multivessel disease 38 40 NS
arget artery NS
LAD 54 44
RCA 20 25
LCx 26 32
Moderate/severe tortuosity 4 9 NS
Angulation 45° 7 18 0.036
arget lesion
ACC/AHA lesion classes B2–C 64 60 NS
Moderate/severe calcification 19 5 0.017
ata are presented as the mean value  SD or percentage.
ACC  American College of Cardiology; AHA  American Heart Association;AD  left anterior descending coronary artery; LCx  left circumflex coronary
rtery; MI  myocardial infarction; RCA  right coronary artery. Datients in the DS and predilation groups, respectively
Table 2). The investigators tended to post-dilate DS less
ften (28% vs. 43%, p  0.06).
uantitative coronary angiography. Reference vessel di-
meter was similar in both subgroups, but MLD at baseline
as significantly greater (1.00 vs. 0.83 mm, p  0.001), and
onsequently, baseline diameter stenosis was significantly
ess (61.6% vs. 68.1%, p  0.001) in the DS subgroup
Table 3). Stent implantation resulted in identical immedi-
able 2. Procedural Characteristics
Predilation
(n  168)
Direct
Stenting
(n  57)
p
Value
rocedure duration (min) 54.1 31.2 34.5  16.3  0.001
luoroscopy time (min) 12.6 8.9 8.3  7.0 0.002
tent implantation
Single stent/multiple
stents (%)
49/51 60/40 NS
Total stent length (mm) 24.1  6.8 23.6  7.4 NS
Total stent length/lesion
length ratio
1.6 (0.7–5.2) 1.6 (0.9–3.7) NS*
Maximum deployment
pressure (atm)
14.2  2.8 14.2  2.3 NS
Postdilation (%) 43 28 0.06
Using the Mann-Whitney U test. Data are presented as the mean value  SD,
ercentage, or median value (range).
able 3. Quantitative Coronary Angiography
Predilation
(n  168)
Direct
Stenting
(n  57)
p
Value
esion length (mm) 14.9 5.4 14.4  6.0 NS
eference vessel diameter (mm)
Before intervention 2.60 0.36 2.62  0.33 NS
After intervention 2.65 0.35 2.69  0.36 NS
At 8 months 2.63  0.33 2.64  0.34 NS
inimum lumen diameter (mm)
Before intervention 0.83 0.30 1.00  0.29  0.001
After intervention
In-stent 2.45 0.29 2.44  0.37 NS
In-lesion 2.18 0.36 2.17  0.43 NS
At 8 months
n 148 51
In-stent 2.24 0.47 2.36  0.45 NS
In-lesion 1.99 0.46 2.08  0.46 NS
Late loss (mm)
In-stent 0.21 0.41 0.10  0.31 0.07
In-lesion 0.19 0.41 0.10  0.33 NS
iameter stenosis (%)
Before intervention 68.1 10.6 61.6  10.1  0.001
After intervention
In-stent 6.9 8.6 8.8  8.6 NS
In-lesion 17.6 8.8 19.7  9.7 NS
At 8 months
n 148 51
In-stent 14.4 15.8 10.7  12.4 NS
In-lesion 24.3 14.5 21.8  11.6 NS
inary restenosis (%)
In-stent 3.4 (5/148) 2.0 (1/51) NS
In-lesion 6.1 (9/148) 2.0 (1/51) NSata are presented as the mean value  SD or percentage (n/N).
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Angiographic follow-up at eight months was obtained
rom 148 patients in the predilation (88.1%) and 51 patients
n the DS subgroup (89.5%). Slightly higher mean values in
n-stent and in-lesion MLD were noted in the DS subgroup
in-stent: 2.36 vs. 2.24 mm, p  0.12; in-lesion: 2.08 vs.
.99 mm, p  0.26). In-stent late loss was 50% lower in
he DS subgroup (0.10 vs. 0.21 mm, p  0.073; Fig. 1)
in-lesion: 0.10 mm for DS vs. 0.19 mm for predilation)
Table 3). In-lesion binary restenosis was 67% less in the
S subgroup (2.0% vs. 6.1%, p  0.46; relative risk 0.32,
5% confidence interval [CI] 0.04 to 2.48).
A multivariate model of in-lesion binary restenosis
ielded no statistically significant impact of DS.
linical follow-up. In-hospital non–Q-wave MIs oc-
urred in three predilation group patients (1.8%); one
atient in the DS group (1.8%) developed stent thrombosis
nside two abutting stents that evolved into a Q-wave MI
nd necessitated TLR (Table 4).
At one year, MACE and TLR rates in the DS group
ere 40% and 67% less than that in the predilation group:
elative risks 0.59 (95% CI 0.18 to 1.96) and 0.33 (95% CI
.04 to 2.53), respectively (Table 4, Fig. 2). One-year
vent-free survival was 94.7% (DS) versus 91.0% for
ACE (predilation, p  0.37) and 98.2% versus 94.6% for
LR (p  0.26).
ISCUSSION
he pooled SES data from the E- and C-SIRIUS trials
ere used to assess the impact of DS on angiographic and
linical outcomes. The analysis was prespecified and accept-
ble because the trials had identical patient and lesion
nclusion criteria.
Our analysis revealed that DS of the SES was as feasible
nd efficacious as balloon-facilitated stenting, with 100%
echnical success achieved in both subgroups and no cross-
vers from DS. Multiple stents were implanted in 40% and
1% of patients, respectively, and in-lesion late loss and
n-lesion binary restenosis at eight months were not statis-
ically different. Thus, anxieties regarding a loss of polymer
r drug appear to be unfounded. There were no safety
oncerns at one month or one year associated with DS of
igure 1. Mean eight-month late loss at the proximal (Prox.) stent margin,
ithin the stent, and at the distal (Dist.) stent margin. Open bars 
redilated lesions; solid bars  directly stented lesions.he SES.
m
Dtudy limitations. This analysis needs cautious interpreta-
ion. Assignment to either balloon-facilitated stenting or
S was not randomized, with a significantly lower preva-
ence of moderately to severely calcified lesions and a
ignificantly lower baseline diameter stenosis in DS. How-
ver, coronary artery angulation more often exceeded 45°,
nd operators tended to post-dilate less frequently in this
roup.
linical implications. When SES implantation is consid-
red, DS appears as safe and efficacious as predilation.
rovided the targeted coronary artery lesion lends itself to
S, this approach is associated with good mid-term angio-
raphic and clinical outcomes. Preprocedural MLD is a
redictor of restenosis after stenting, as are reference vessel
iameter and post-procedural MLD (9). The larger prepro-
edural MLD may have accounted for the trend toward
ower eight-month angiographic and improved one-year
able 4. Major Adverse Events*
Predilation
(n  168)
Direct
Stenting
(n  57)
p
Value
n-hospital events
Death 0 0 —
MI 3 (1.8) 1 (1.8) NS
Q-wave 0 1 (1.8) NS
Non–Q-wave† 3 (1.8) 0 NS
Emergency CABG 0 0 —
TLR 0 1 (1.8) NS
Stent thrombosis 0 1 (1.8) NS
Total in-hospital MACE 3 (1.8) 1 (1.8) NS
umulative in- and out-of-
hospital events at 1 year
Death 2 (1.2) 0 NS
MI 7 (4.2) 3 (5.3) NS
Q-wave 1 (0.6) 2 (3.5) NS
Non–Q-wave† 6 (3.6) 1 (1.8) NS
Emergency CABG 1 (0.6) 0 NS
TLR 9 (5.4) 1 (1.8) NS
Stent thrombosis 2 (1.2) 1 (1.8) NS
Total MACE at 1 year 15 (8.9) 3 (5.3) NS
Non-hierarchical listing. †Non–Q-wave myocardial infarction (MI) defined as
levation of postprocedural creatine kinase serum levels to more than twice the upper
imit of normal, with elevated creatine kinase-MB isoenzyme serum levels in the
bsence of new pathologic Q-waves. Data are presented as the number (%) of patients.
CABG coronary artery bypass grafting; MACEmajor adverse cardiac events;
LR  target lesion revascularization.
igure 2. Rates of major adverse cardiac events (MACE) and target lesion
evascularization (TLR) at one year. Both clinical outcome variables are
arkedly, although non-significantly, reduced in patients who underwent
S (solid bars). Open bars  predilation.
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ate loss and the lack of restenosis outside the stent associ-
ted with DS are noteworthy. The lack of statistical signif-
cance of the differences in outcomes after DS and predila-
ion strategy may be due to a type II statistical error, but
ay indicate there are no true differences. A randomized
rial powered to detect any such difference is warranted.
These results are in concordance with a recent post hoc
nalysis of the TAXUS-II trial (10) and are supported by
he Direct Stenting Using the Sirolimus-Eluting Stent
DIRECT) trial (11), which compared a group of 225
atients who underwent DS with a historical predilated
ES group from the SIRIUS trial (6). The latter investiga-
ion concluded that “direct stenting was non-inferior to
re-dilation for all (clinical and angiographic) endpoints
ssessed.”
onclusions. The DS of SES performed at the investiga-
or’s discretion proved feasible, safe, and efficacious in terms
f angiographic and mid-term clinical outcomes. Concerns
hat drug-eluting stents may be less effective when deployed
ithout predilation because of polymer and/or drug loss
ppear unfounded.
eprint requests and correspondence: Dr. Joachim Schofer,
thmarscher Kirchenweg 168, D-22763 Hamburg, Germany.
-mail: schofer@center-for-cardiology.de.
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